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EDITORIAL
Is there a pharmacologic basis for combination renin axis
blockade?
Interruption of the renin axis with an angiotensin-
converting enzyme (ACE) inhibitor or an angiotensin re-
ceptor blocker (ARB) in the patient at risk of end-stage
renal disease is now well established [1–4]. These same
studies also show that many patients progress despite
the use of an ACE inhibitor or ARB. One can argue that
we have now entered a new era in which attempts to op-
timize renin axis blockade are being explored in the hope
that more complete blockade will lead to a better ther-
apeutic outcome. Use of an ACE inhibitor:ARB com-
bination has received most attention [5–7]. Alternatives
include the use of very high doses of ARBs, the combi-
nation of an ACE inhibitor or ARB with an agent that
blocks the effects of aldosterone [8, 9] and, most recently,
the promise of renin inhibition [10].
The possibility that an ACE:ARB combination might
improve therapeutics was received enthusiastically by
the nephrology community. Andersen and Mogensen re-
cently reviewed the 10 combination studies reported in
patients with diabetic nephropathy and the 8 combina-
tion studies in patients with nephropathy unrelated to
diabetes [5]. They reported that 5 of the 10 studies in dia-
betic nephropathy showed an improvement in the reduc-
tion of proteinuria with combination therapy: The others
did not. A similar pattern was reported for nondiabetic
nephropathy. One limitation of most of the combination
studies involves the attention paid to the issue of dose.
Despite its obvious importance, this issue of dose often
escapes the medical community. In the ALLHAT Study,
for example, which did not show the anticipated favorable
influence of ACE inhibition on nephropathy, the decision
was made to start treatment with 10 mg of lisinopril daily.
Few of us would think that that was an adequate dose
for ACE inhibition. We still do not know how many pa-
tients in that study remained on that dose. If a substantial
number did, then we would have to conclude that ACE
inhibitor therapy was not really tested.
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The issue of dose and its role in pharmacology and ther-
apeutics has recently been reviewed by Dr. Stata Norton
in an article with the piquant title “The origins of phar-
macology in the sixteenth century” [11]. The crucial role
of dose in treatment was apparently first recognized by
Paracelsus almost 500 years ago. Over 300 years ago,
DeMoivre reported the equations that describe the nor-
mal distribution of a variable. In 1879, Galton argued
that the variation in individual responses was related to
that curve of normal distribution. Shortly thereafter, Paul
Ehrlich argued that there were actually two sigmoid dose-
response relationships (Fig. 1). One dose response was
for the primary therapeutic effect. The second dose re-
sponse was for adverse effects of the drug. Paracelsus had
come to a similar conclusion several hundred years ear-
lier. The farther apart that these two sigmoid curves were,
the better tolerated or safer the drug. In the case of ACE
inhibitors, this issue is important. We quickly run into ad-
verse effect, as we attempt to raise ACE inhibitor dose.
Conversely, in the case of the ARBs, we do not seem to
have identified, yet, the toxic dose. Few drugs in history
have been as well tolerated.
The sigmoid-shaped dose-response relationship is ac-
tually the integral of a normal distribution. From that, sev-
eral things follow. The wide use of the ED50 and ID50
(the dose inducing 50% of the maximum response and
the dose inducing a 50% reduction in response) follow
because the 50% dose is the point at which the variance
is minimal. Another feature is that the response will rise
linearly over the range 16% of maximal to 84% of max-
imal. The inflection point in the dose-response relation-
ship occurs at these two points.
Do these relationships, typically worked out in sim-
ple systems in vitro, apply to the intact organism? More
specifically, do they apply to renin axis blockade? The
answer is clearly “yes.” Figure 2 displays the relation be-
tween eprosartan dose and the renal hemodynamic re-
sponse in healthy subjects in balance on a low-salt diet
to maximize the response [12]. The threshold dose was
10 mg, which produced a small but statistically signifi-
cant response (Fig. 2). A 50 mg dose induced a response
that was below maximum but well above the ED50. With
a 100 mg dose, a rise of 135 ± 20 mL/min/1.73m2 was
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Fig. 1. Dose-response relationships. At dose X1 50% of a population
shows the desired action (A), and at dose X2 50% of the same popula-
tion shows an undesired action or side effect (B).
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Fig. 2. Peak change in RPF are plotted in relation to eprosartan dose
in subjects in balance on a low salt diet.
identified near, but not at the maximum. Doubling and
quadrupling the dose to 200 mg and 400 mg induced a
significant trend for an increase that accrued more grad-
ually. As an 800 mg dose was not employed, we do not
know whether a maximum had been achieved.
To return to the issue of ACE:ARB combinations, one
could argue that an optimal approach would employ the
eprosartan dose at its inflection point, 100 mg, and add
an ACE inhibitor at its upper inflection point to achieve
more complete blockade. The price that one pays is the
increased possibility of toxicity from the use of a second
drug. There are now three studies near completion of very
high-dose ARB employed in patients with type 2 diabetes
and proteinuria. If it should turn out that 640 mg of valsar-
tan, or 900 mg of irbesartan, or 128 mg of candesartan—
the top doses used in the three studies—are much more
effective in reducing proteinuria than is the usual dose
employed for blood pressure, the ACE:ARB combina-
tion will have to be assessed, once again, with the use
of that high-dose ARB. A fundamental question is in-
volved. If the ACE inhibitor is bringing to the therapeutic
table something beyond renin axis blockade, perhaps via
bradykinin, nitric oxide, or other pathways, then the ACE
inhibitor should be considered for routine therapy. If the
ACE inhibitor under those circumstances adds nothing,
then the decision is clinical. Is the cost of the drug reduced
by using the combination? ACE inhibitors have become
inexpensive. One hopes that success in this area will in-
duce the pharmaceutical companies involved to consider
flat pricing.
In this era of renin axis inhibition optimization, we will
also have to learn how to combine these agents, in their
appropriate dose, with an agent that blocks the effects
of aldosterone. Interesting preliminary data are already
available [8, 9], but we will have to learn how to deal with
the issue of hyperkalemia.
In a study still reported only in an abstract, Epsein et al
[9] evaluated the influence on proteinuria in patients with
type 2 diabetes of eplerenone alone, enalapril alone, and
a combination of the two agents. The 266 patients with
type 2 diabetes mellitus had mild-to-moderate hyperten-
sion and proteinuria. In that 24-week double-blind study,
eplerenone decreased microalbuminuria independent of
its antihypertensive activity. The renoprotective proper-
ties of eplerenone were significantly better than enalapril
used alone. The reduction in albumin excretion with com-
bination therapy, however, was significantly more effec-
tive than monotherapy with either drug. Indeed, albumin
excretion was reduced by 74% (95%CI 67–79) in the com-
bination group, a remarkable therapeutic response. Hy-
perkalemia was frequent. More patients were withdrawn
for hyperkalemia in the combination group [13] than in
the eplerenone group [6] or the enalapril group [2].
Given the remarkable therapeutic effect, it is reason-
able to believe that an investment in the management of
hyperkalemia may prove to be useful [14]. Approaches
available include a reduction in the eplerenone dose,
the combination of eplerenone with potassium-wasting
diuretics such as chlorthaladone, but more novel ap-
proaches exist [13]. Moskowitz has suggested the use of
a mineralocorticoid (florinef) to lower serum potassium
concentration in such patients, employing furosemide or
another loop diuretic to prevent fluid retention. Surely,
some combination of these maneuvers will help to deal
with the problem of hyperkalemia.
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As renin inhibitors work at the rate-limiting step, and
there are compelling reasons that the rate-limiting step
be addressed in combination therapy [10], we will also
have to learn how to incorporate these possibilities into
our therapeutic planning.
Those of us who enjoy this area can look forward to a
great deal of fun and the development of more effective
treatment options in the next decade.
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